Beijing Zhongyin Technology

Beijing Zhongyin Technology Co., Ltd. (Chigenovo) is a national high-tech enterprise founded in 2016, specializing in gene therapy for hereditary eye diseases. The company provides a "one-stop" solution that encompasses clinical gene diagnosis, drug research and development, and treatment for patients with genetic eye diseases. The founding team, including Professor Yang Liping and Zhong Xiancheng, has over two decades of experience in the genetic eye disease field. Professor Yang, who earned a doctorate in ophthalmology from Peking University Medical Department, leverages extensive clinical and research expertise to guide the company's focus.

The company's business model is built around a comprehensive drug development system that includes target screening, basic research, animal and stem cell validation, AAV (adeno-associated virus) vector R&D, and clinical trial operations. Chigenovo employs a dual-technology platform approach, utilizing both gene replacement and gene editing therapies to address different genetic mutation mechanisms. Its clinical gene diagnosis platform has created a substantial database of genetic eye diseases in China, which informs the selection of therapeutic targets for drug development. Revenue is generated through providing precise genetic testing services and developing gene therapy drugs.

Chigenovo has several drug pipelines in development. Its leading drug candidate, ZVS101e, is a gene replacement therapy for Bietti's Crystalline Dystrophy (BCD) caused by CYP4V2 gene mutations. This drug has received Orphan Drug Designation (ODD) from the U.S. FDA and has advanced to late-stage clinical trials. Another key product, ZVS203e, is an in-vivo gene editing therapy that has also been granted ODD by the FDA. The company has secured multiple rounds of funding from investors including Kunlun Capital, Jinpu Investment, and Longpan Investment, which has accelerated the clinical and industrialization progress of its drug pipelines.

Keywords: gene therapy, ophthalmology, hereditary eye diseases, genetic diagnosis, AAV vector, drug development, Bietti's Crystalline Dystrophy, gene replacement therapy, gene editing, clinical trials, orphan drug, ZVS101e, CYP4V2, Chigenovo, inherited retinal diseases, precision medicine, biotechnology, pharmaceutical, vision loss, genetic testing